Author: sugaradmin

Introduction and Objective: Gestational diabetes (GDM) increases risk of type 2 diabetes (T2D). We examined associations between nativity and glucose tolerance at 6-9 wks postpartum in women with recent GDM.Methods: 995 women with GDM and without T2D based on 2-h 75g oral glucose tolerance tests were classified with normoglycemia (fasting <100 and 2-h post-load <140 […]

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a paradigm shift in treating obesity. The substantial weight loss observed in clinical trials improves weight-related comorbidities. However, weight loss reported in the real world has been less than that seen in clinical trials. One hypothesis for this gap is that patients may not complete the […]

Introduction and Objective: Utreglutide (UTG, GL0034), a once weekly glucagon-like peptide-1 receptor agonist, demonstrated body weight (BW) reduction up to 3.3 kg after single dose and improvements in cardio-metabolic biomarkers after multiple ascending doses in obese subjects. This phase 1 trial assessed the safety and efficacy of UTG in overweight and obese subjects.Methods: The study […]

Introduction and Objective: Syndromic diabetes refers to the co-occurrence of diabetes with abnormalities of organ systems beyond the endocrine pancreas. RADIANT was established to study atypical forms of diabetes including syndromic diabetes. We aimed to characterize individuals with putative syndromic forms of diabetes in RADIANT.Methods: We defined syndromic diabetes based on 1 major and 1 […]

Introduction and Objective: Fasting during Ramadan puts people with type 1 diabetes (PWT1D) at risk of dysglycemia and diabetic ketoacidosis (DKA). Recent studies have shown the clinical effectiveness of automated insulin delivery (AID) systems in PWT1D who fast during Ramadan. Here, we compare the effectiveness and safety profiles of the Medtronic 780G versus Tandem Control-IQ […]

Introduction and Objective: Most people with type 1 diabetes (PWT1D) are advised to not fast during Ramadan because of dysglycemia risks. We compared efficacy, safety profiles, and fear of hypoglycemia (FH) during Ramadan fasting in users of 4 insulin delivery modalities.Methods: Four treatment groups were compared: automated insulin delivery (AID) (n=114), sensor augmented pump (SAP) […]

Introduction and Objective: Glycemic control in diabetes can differ from person to person and automated insulin delivery (AID) with frequent autocorrections provides more personalized diabetes management. The present study assessed glycemic outcomes and insulin use of MiniMed™ 780G system (MM780G) users with different daily carbohydrate intake.Methods: CareLink™ personal data (as of October 26, 2024) of […]

Introduction and Objective: Management of dysglycemia in older adults with insulin-requiring diabetes can be challenging and automated insulin delivery is reported to improve glycemic outcomes in this population.1,2 The present study evaluated MiniMedTM 780G system (MM780G) performance in a real-world US population aged ≥65 years.Methods: CareLink™ data (up to December 18, 2024) of consenting US […]

Introduction and Objective: Type 2 diabetes (T2D) and obesity are associated with left ventricular (LV) dysfunction, but the impact of exercise interventions on LV function remains unclear. This study aims to assess LV function in individuals with obesity, with and without T2D via supervised aerobic exercise training, using cardiac MRI and time-resolved three-dimensional phase-contrast MRI […]

Introduction and Objective: Systemic inflammation promotes insulin resistance (IR) and comorbidities like type 2 diabetes. Multiple CD4+ T cell subsets support inflammation in people with excess weight or obesity (herein, obesity). Autophagy is one key mechanism that regulates T cell-generated cytokines and thus inflammation. We tested the hypothesis that obesity-associated changes in T cell autophagy […]